{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:19:41Z","timestamp":1772104781430,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00939","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T12:41:48Z","timestamp":1593175308000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Probable Drug Interaction Between Etanercept and Cyclosporine Resulting in Clinically Unexpected Low Trough Concentrations: First Case Report"],"prefix":"10.3389","volume":"11","author":[{"given":"Haini","family":"Wen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoyang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"B1","unstructured":"Humira (adalimumab) package insert2020"},{"key":"B2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","article-title":"Methods for causality assessment of adverse drug reactions: A systematic review","volume":"31","author":"Agbabiaka","year":"2008","journal-title":"Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.beem.2013.05.011","article-title":"Heterophilic antibody interference in immunometric assays","volume":"27","author":"Bolstad","year":"2013","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0006-2952(98)00372-4","article-title":"Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy","volume":"57","author":"Elkahwaji","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"B5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-3-319-72422-5_5","article-title":"Drug-Cytokine Interactions","volume-title":"Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions","author":"Goralski","year":"2018"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1345\/aph.1H018","article-title":"Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures","volume":"40","author":"Hess","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1345\/aph.1H423","article-title":"Proposal for a new tool to evaluate drug interaction cases","volume":"41","author":"Horn","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/clpt.2009.308","article-title":"Therapeutic protein-drug interactions and implications for drug development","volume":"87","author":"Huang","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40262-019-00810-z","article-title":"Update on Therapeutic Protein\u2013Drug Interaction: Information in Labeling","volume":"59","author":"Jing","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11319980-000000000-00000","article-title":"CYP-mediated therapeutic protein-drug interactions: Clinical findings, proposed mechanisms and regulatory implications","volume":"49","author":"Lee","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40262-016-0462-8","article-title":"Disease\u2013Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis","volume":"56","author":"Lee","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2169\/internalmedicine.53.1136","article-title":"Comparison of glucocorticoids alone and combined with cyclosporine A in patients with IgA nephropathy: A prospective randomized controlled trial","volume":"53","author":"Liu","year":"2014","journal-title":"Intern. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1093\/ndt\/gfr002","article-title":"Clinically unexpected cyclosporine levels using the ACMIA method on the RXL dimension analyser","volume":"26","author":"Morelle","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"B14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1124\/dmd.107.018747","article-title":"Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer","volume":"36","author":"Morgan","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"B15","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/14397595.2017.1366006","article-title":"Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis","volume":"28","author":"Murdaca","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1373\/clinchem.2014.224816","article-title":"Usefulness of a thyroglobulin liquid chromatography-tandem mass spectrometry assay for evaluation of suspected heterophile interference","volume":"60","author":"Netzel","year":"2014","journal-title":"Clin. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/rheumatology\/kei090","article-title":"Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A","volume":"45","author":"Nowlan","year":"2005","journal-title":"Rheumatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.3390\/jcm8101584","article-title":"Has The Time Arrived to Refine The Indications of Immunosuppressive Therapy and Prognosis in IgA Nephropathy","volume":"8","author":"Obri\u0219c\u0103","year":"2019","journal-title":"J. Clin. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/1529-0131(200004)43:4<944::AID-ANR29>3.0.CO;2-Y","article-title":"Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays","volume":"43","author":"Russell","year":"2000","journal-title":"Arthritis Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40264-014-0262-8","article-title":"Consensus Recommendations for Systematic Evaluation of Drug\u2013Drug Interaction Evidence for Clinical Decision Support","volume":"38","author":"Scheife","year":"2015","journal-title":"Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/675108","article-title":"Ankylosing Spondylitis and Rheumatoid Arthritis: Serum Levels of TNF-\u03b1 and Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab","author":"Schulz","year":"2014","journal-title":"BioMed. Res. Int"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-017-0467-z","article-title":"Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis","volume":"18","author":"Song","year":"2017","journal-title":"BMC Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/s0140-6736(00)02822-1","article-title":"Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients","volume":"356","author":"Strehlau","year":"2000","journal-title":"Lancet (London England)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.cyto.2015.04.011","article-title":"Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis","volume":"75","author":"Takeshita","year":"2015","journal-title":"Cytokine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/phar.2279","article-title":"Falsely Elevated Vancomycin Concentrations in a Patient Not Receiving Vancomycin","volume":"39","author":"Tsoi","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jac\/dkw349","article-title":"Voriconazole metabolism is influenced by severe inflammation: A prospective study","volume":"72","author":"Veringa","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/cei.12782","article-title":"The impact of disease activity and tumour necrosis factor-\u03b1 inhibitor therapy on cytokine levels in juvenile idiopathic arthritis","volume":"184","author":"Walters","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/0190-9622(90)70358-O","article-title":"The role of cytochromes P-450 in cyclosporine metabolism","volume":"23","author":"Watkins","year":"1990","journal-title":"J. Am. Acad. Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1476-5381.2009.00206.x","article-title":"Current status and challenges of cytokine pharmacology","volume":"157","author":"Z\u00eddek","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1080\/17425255.2016.1211109","article-title":"Therapeutic protein-drug interactions: plausible mechanisms and assessment strategies","volume":"12","author":"Zhou","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1177\/0091270004273321","article-title":"Clinical pharmacokinetics of etanercept: A fully humanized soluble recombinant tumor necrosis factor receptor fusion protein","volume":"45","author":"Zhou","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1002\/acr.20575","article-title":"Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI)","volume":"63","author":"Zochling","year":"2011","journal-title":"Arthritis Care Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1136\/ard.62.6.561","article-title":"Up regulation of the production of tumour necrosis factor \u03b1 and interferon \u03b3 by T cells in ankylosing spondylitis during treatment with etanercept","volume":"62","author":"Zou","year":"2003","journal-title":"Ann. Rheumatol. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00939\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T12:41:51Z","timestamp":1593175311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00939\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":34,"alternative-id":["10.3389\/fphar.2020.00939"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00939","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"article-number":"939"}}